China's NMPA has approved the combination of ELUNATE (fruquintinib) and TYVYT (sintilimab) for treating patients with locally advanced or metastatic renal cell carcinoma who failed prior VEGFR-TKI therapy and have not received PD-1/PD-L1 inhibitors. This approval is based on the FRUSICA-2 study, which showed a 63% reduction in risk of disease progression or death, with a median progression-free survival of 22.2 months compared to 6.9 months for standard therapies. The combination demonstrated a higher objective response rate and longer duration of response, offering a promising second-line treatment option in China where options are limited. Further survival data is still maturing, and the safety profile aligns with known effects of the drugs.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
